의료기기 이야기

The demand for medication to be delivered using autoinjectors is rising internationally, responding to the increased incidence rates of chronic conditions and the emerging treatments for those chronic conditions. Autoinjectors are used to deliver medication to treat Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Crohn’s Disease, among others. It is reasonable to assume that some autoinje..

1. BORDERLINE PRODUCTS: MEDICAL DEVICES / MEDICINAL PRODUCTS  1.1 IntroductionThe demarcation between the Regulation (EU) 2017/745 on medical devices (MDR) on the one hand and the Directive 2001/83/EC on the Community code relating to medicinal products for human use (MPD) on the other hand is crucial for the proper implementation of these sets of legislation and their correct interpretation and..

Introduction – Objectives of the MDR/IVDR amendment The amendment of the MDR and of the IVDR through Regulation (EU) 2024/1860 addresses three topics: 1. Regulation (EU) 2024/1860 aims to ensure a high level of patient safety and public health protection, including the mitigation of risks related to discontinuation or interruption of supply of in vitro diagnostic medical devices (IVDs) needed fo..

You might have heard some rumors already: Several European parliamentarians sent a joint motion for resolution to the European Commission (EC). On October 21st, 2024, a European Parliament resolution “on the urgent need to revise the Medical Devices Regulation” (2024/2849(RSP)) was submitted to the EC. In addition, the Heads of Medicines Agencies (HMA, heads of EU Competent Authorities responsib..

SummaryOn October 24, 2024, the U.S. Food and Drug Administration (FDA) will host a webinar for laboratory manufacturers and other interested parties to discuss the FDA’s Total Product Life Cycle (TPLC) approach to the oversight of in vitro diagnostic products (IVDs). The FDA’s TPLC approach allows the FDA to review and monitor medical devices throughout their life cycle by taking into account a..

BackgroundIn recent years, the TGA has enacted several reforms to advance regulatory harmonization or reliance. Manufacturers are able to leverage existing conformity assessment evidence issued by a comparable overseas regulator or assessment body as the Manufacturer Evidence to support an application to add a medical device or IVD to the Australian Register of Therapeutic Goods (ARTG). Further ..

Introduction The purpose of this guidance document is to clarify what products fall in scope of Regulation 2017/746 on in vitro diagnostic medical devices (IVDR) – also referred to as ‘qualification’ as an in vitro diagnostic medical device (IVD) or an accessory to an IVD. In order to be qualified as an IVD or an accessory to an IVD, the product must fulfil the definition in Art 2(2) or Art 2(4)..

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Regulation (EU) 2024/1860 and IVDR Compliance in Europe▶ 일시: 2024년 10월 16일 CST 9시 (한국시간: 10월 16일 23시)  Are you an IVD medical device manufacturer who needs a better understanding of what action you will need to take and when so that you can make use of the extension under the revised Regulation (EU) 2024/1860. The European Commission amended the In Vitro Diagnost..

According to Regulation (EU) 2017/746 on in vitro diagnostic medical devices (the IVDR), as part of conformity assessment of class D in vitro diagnostic medical devices (IVDs), the manufacturer must submit an application to a notified body. In addition to the assessment by the notified body, under certain conditions particular elements may be reviewed by an expert panel and/or tested by an EU re..

Returning from a long holiday and need to catch up on EU medical device and IVD regulatory developments? Read our update on European regulatory news over the last few months. Amending legislation published to extend the transition of legacy IVDs and roll out EUDAMEDRegulation 2024/1860 was officially released to extend the transition time for legacy IVDs, roll out EUDAMED, and require data on di..